MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Join SI Premium – FREE
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q2 EPS of ($0.87), $0.15 worse than the analyst estimate of ($0.72).
For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Active options: META RIOT PLTR CRWV NFLX SMCI SOFI GOOG IREN HOOD
- Livanova (LIVN) PT Raised to $115 at Mizuho
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
